The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder : protocol and clinical characteristics of the INCAS study
Brynte, Christoffer (Karolinska Institutet (Estocolm, Suècia))
Aeschlimann, Myriam (University of Bern)
Barta, Csaba (Semmelweis University)
Begeman, Alex Hendikus Abraham (De Hoop Ggz)
Bäcker, Amanda (Karolinska Institutet (Estocolm, Suècia))
Crunelle, Cleo Lina (Vrije Universiteit Brussel)
Daigre, Constanza (Hospital Universitari Vall d'Hebron. Institut de Recerca)
De Fuentes-Merillas, Laura (Novadic-Kentron Addiction Care)
Demetrovics, Zsolt (University of Gibraltar)
Dom, Geert (PC Multiversum)
Grau-López, Lara (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Icick, Romain (Université de Paris Cité)
Johnson, Brian (SUNY Upstate University)
Joostens, Peter (Alexianen Zorggroep Tienen)
Kapitány-Fövény, Máté (National Institute of Mental Health)
Karsinti, Emily (Université Paris-Nanterre)
Kiefer, Falk (Mannheim Center for Translational Neurosciences)
Konstenius, Maija (Karolinska Institutet (Estocolm, Suècia))
Levin, Frances R. (New York State Psychiatric Institute)
Luderer, Mathias (University Hospital of Frankfurt (Alemanya))
Markus, Wiebren (Iriszorg Addiction Care)
Matthys, Frieda (Vrije Universiteit Brussel)
Moggi, Franz (University Hospital of Psychiatry)
Palma-Álvarez, Raúl Felipe (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Paraskevopoulou, Maria (RadboudumcDonders Institute for Brain)
Ramos-Quiroga, Josep Antoni (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Schellekens, Arnt (Nijmegen Institute for Scientist Practitioners in Addiction)
Soravia, Leila M. (Südhang Clinic)
Therribout, Norman (Université Paris-Nanterre)
Thomas, Anil (NYU Grossman School of Medicine)
van de Glind, Geurt (University of Applied Sciences-Utrecht)
van Kernebeek, Michiel Willem (Vrije Universiteit Brussel)
Vollstädt-Klein, Sabine (University of Heidelberg)
Vorspan, Florence (Université de Paris Cité)
van den Brink, Wim (Amsterdam UMC. University Medical Center)
Franck, Johan (Karolinska Institutet (Estocolm, Suècia))
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Substance use disorders (SUD) often co-occur with attention deficit hyperactivity disorder (ADHD). Although the short-term effects of some specific interventions have been investigated in randomized clinical trials, little is known about the long-term clinical course of treatment-seeking SUD patients with comorbid ADHD. This paper presents the protocol and baseline clinical characteristics of the International Naturalistic Cohort Study of ADHD and SUD (INCAS) designed and conducted by the International Collaboration on ADHD and Substance Abuse (ICASA) foundation. The overall aim of INCAS is to investigate the treatment modalities provided to treatment-seeking SUD patients with comorbid ADHD, and to describe the clinical course and identify predictors for treatment outcomes. This ongoing study employs a multicentre observational prospective cohort design. Treatment-seeking adult SUD patients with comorbid ADHD are recruited, at 12 study sites in nine different countries. During the follow-up period of nine months, data is collected through patient files, interviews, and self-rating scales, targeting a broad range of cognitive and clinical symptom domains, at baseline, four weeks, three months and nine months. A clinically representative sample of 578 patients (137 females, 441 males) was enrolled during the recruitment period (June 2017-May 2021). At baseline, the sample had a mean age (SD) of 36. 7 years (11. 0); 47. 5% were inpatients and 52. 5% outpatients; The most prevalent SUDs were with alcohol 54. 2%, stimulants 43. 6%, cannabis 33. 1%, and opioids 14. 5%. Patients reported previous treatments for SUD in 71. 1% and for ADHD in 56. 9%. Other comorbid mental disorders were present in 61. 4% of the sample: major depression 31. 5%, post-traumatic stress disorder 12. 1%, borderline personality disorder 10. 2%. The first baseline results of this international cohort study speak to its feasibility. Data show that many SUD patients with comorbid ADHD had never received treatment for their ADHD prior to enrolment in the study. Future reports on this study will identify the course and potential predictors for successful pharmaceutical and psychological treatment outcomes. ISRCTN15998989 20/12/2019.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	ADHD ; Comorbidity ; SUD
Publicat a:	BMC Psychiatry, Vol. 22 (september 2022) , ISSN 1471-244X

DOI: 10.1186/s12888-022-04259-6
PMID: 36151539

8 p, 704.8 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats